Coherus Oncology, Inc.
Clinical trials sponsored by Coherus Oncology, Inc., explained in plain language.
Biopharmaceutical company focused on oncology immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug CHS-114 enters first human tests Results expected Sep 2026 (estimated)
- New cocktail aims to shrink untreatable liver tumors Results expected Sep 2027 (estimated)
-
New antibody drug takes on Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…
Phase 1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo shows promise in liver cancer trial
Disease control CompletedThis phase 2 trial tested whether adding an experimental drug called SRF388 to a standard two-drug regimen (atezolizumab plus bevacizumab) helps people with advanced liver cancer that hasn't been treated before. The study enrolled 30 adults whose cancer could not be surgically re…
Phase 2 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC